http://www.reportlinker.com/ci02233/Biological-Therapy.html Wed, 22 May 2013 16:52:41 +0000 helpdesk@reportlinker.com Copyright 2013, Reportlinker Zend_Feed en-us http://blogs.law.harvard.edu/tech/rss http://www.reportlinker.com/d014266438/StemCells-Inc-Company-Report-for-Year-2013.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public http://www.reportlinker.com/d014266438/StemCells-Inc-Company-Report-for-Year-2013.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public ... Biotechnology company. Gfap and nestin are proteins that are co-expressed by certain key cells found in the human central nervous system. Each patent claims a cell culture of undifferentiated gfap+ nestin+ cells ...]]> Thu, 28 Feb 2013 23:00:00 +0000 http://www.reportlinker.com/d014230130/Company-Report-Biological-Therapy-in-Australia-for-Year-2013.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public http://www.reportlinker.com/d014230130/Company-Report-Biological-Therapy-in-Australia-for-Year-2013.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public ... With csiro shows cardiocel tissues patches can be used as a matrix for delivering stem cells 6-feb-13 ubi universal bio. Colin adam to retire as non-executive director at the next agm 6-jan-13 avh avita ...]]> Thu, 31 Jan 2013 23:00:00 +0000 http://www.reportlinker.com/d014230303/Company-Report-Stem-Cell-in-The-United-States-for-Year-2013.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public http://www.reportlinker.com/d014230303/Company-Report-Stem-Cell-in-The-United-States-for-Year-2013.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public ... A few. stem cells have the potential to overcome these limitations and act as a more effective form of treatment for a myocardial infarction. A stem cell is classified as an undifferentiated, self ...]]> Thu, 31 Jan 2013 23:00:00 +0000 http://www.reportlinker.com/d014229158/Company-Report-Biological-Therapy-for-Year-2013.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public http://www.reportlinker.com/d014229158/Company-Report-Biological-Therapy-for-Year-2013.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public ... Issues such as research intervention on human beings18; research on human embryos and human embryonic stem cells and non-human primates are automatically submitted for ethics review. To ensure ...]]> Sun, 31 Mar 2013 22:00:00 +0000 http://www.reportlinker.com/d014201754/Company-Report-Stem-Cell-in-The-United-States-for-Year-2013.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public http://www.reportlinker.com/d014201754/Company-Report-Stem-Cell-in-The-United-States-for-Year-2013.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public ]]> Thu, 28 Feb 2013 23:00:00 +0000 http://www.reportlinker.com/d014169159/Company-Report-Biological-Therapy-in-China-for-Year-2013.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public http://www.reportlinker.com/d014169159/Company-Report-Biological-Therapy-in-China-for-Year-2013.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public ]]> Thu, 28 Feb 2013 23:00:00 +0000 http://www.reportlinker.com/d014236881/Company-Report-Biological-Therapy-in-The-United-States-for-Year-2013.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public http://www.reportlinker.com/d014236881/Company-Report-Biological-Therapy-in-The-United-States-for-Year-2013.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public ... From funding. The doc/nist will review research using human embryonic stem cell lines that it supports and conducts in accordance with the common rule and nist implementing procedures, as appropriate ...]]> Sun, 31 Mar 2013 22:00:00 +0000 http://www.reportlinker.com/d014339102/Company-Report-Biological-Therapy-in-The-United-States-and-France-for-Year-2013.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public http://www.reportlinker.com/d014339102/Company-Report-Biological-Therapy-in-The-United-States-and-France-for-Year-2013.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public ]]> Sun, 31 Mar 2013 22:00:00 +0000 http://www.reportlinker.com/d014172209/Cell-Therapy-Market-Analysis-in-The-United-Kingdom.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public http://www.reportlinker.com/d014172209/Cell-Therapy-Market-Analysis-in-The-United-Kingdom.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public ... Of regenerative medicine and cell therapies Support for the development of enabling platform tools and technologies. Proposals to address development issues such as preclinical; formulation and delivery ...]]> Thu, 31 Jan 2013 23:00:00 +0000 http://www.reportlinker.com/d014235785/The-British-Cell-Therapy-Market-Innovation-and-Technology-Trends.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public http://www.reportlinker.com/d014235785/The-British-Cell-Therapy-Market-Innovation-and-Technology-Trends.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public ... therapies in uk clinical trial and clinical use value investible propositions created leading to cell therapy companies that succeed and stay in the uk attractiveness demonstrating that the uk ...]]> Thu, 28 Feb 2013 23:00:00 +0000 http://www.reportlinker.com/p0284905/Analytical-Tool-Cancer-Immunotherapy.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p0284905/Analytical-Tool-Cancer-Immunotherapy.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium "Analytical Tool- Cancer Immunotherapy" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in immunotherapy drug development for the treatment of cancer. It ...]]> Sun, 21 Apr 2013 22:00:00 +0000 http://www.reportlinker.com/p01171945/iPS-cell-Generation-patent-landscape-03.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01171945/iPS-cell-Generation-patent-landscape-03.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium Many diseases such as cardiovascular disorders, diabetes or neurodegenerative diseases are the consequences of dysfunction of specific cells. Strategies were developed to repair or regenerate the damaged ...]]> Tue, 30 Apr 2013 22:00:00 +0000 http://www.reportlinker.com/p0284894/Analytical-Tool-Cancer-Therapeutic-Antibodies.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p0284894/Analytical-Tool-Cancer-Therapeutic-Antibodies.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium "Analytical Tool - Cancer Therapeutic Antibodies" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in antibody drug development for the treatment of cancer. ...]]> Sun, 21 Apr 2013 22:00:00 +0000 http://www.reportlinker.com/p01171946/iPS-cell-Differentiation-patent-landscape-03.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01171946/iPS-cell-Differentiation-patent-landscape-03.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium Many diseases such as cardiovascular disorders, diabetes or neurodegenerative diseases are the consequences of dysfunction of specific cells. Strategies were developed to repair or regenerate the damaged ...]]> Tue, 30 Apr 2013 22:00:00 +0000 http://www.reportlinker.com/p0284906/Immunotherapy-in-Oncology-Drug-Pipeline-Update.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p0284906/Immunotherapy-in-Oncology-Drug-Pipeline-Update.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium Cancer immunotherapy offers an attractive therapeutic addition, delivering treatment of high specificity, low toxicity and prolonged activity. In this Drug Pipeline Update BioSeeker brings together the ...]]> Sun, 21 Apr 2013 22:00:00 +0000 http://www.reportlinker.com/p01120091/B-Cell-Leukemia-Pipeline-Review-H1.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01120091/B-Cell-Leukemia-Pipeline-Review-H1.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium B-Cell Leukemia - Pipeline Review, H1 2013 Summary Global Markets Direct's, 'B-Cell Leukemia - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides ...]]> Wed, 27 Feb 2013 23:00:00 +0000 http://www.reportlinker.com/p0765763/T-Cell-Leukemia-Pipeline-Review-H1.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p0765763/T-Cell-Leukemia-Pipeline-Review-H1.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium This report provides information on the therapeutic development for T-Cell Leukemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players ...]]> Wed, 27 Feb 2013 23:00:00 +0000